Back to Peptides
sexual_healthMedium Risk

Cetrorelix

Also known as: Cetrotide, GnRH antagonist

Half-life:
~62 hours

Administration Routes

subcutaneous injection
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Competitive GnRH receptor antagonist; immediately blocks pituitary GnRH receptors; rapidly suppresses LH/FSH without initial flare effect; used for controlled hormonal suppression

A GnRH antagonist that rapidly suppresses the HPG axis without the initial flare seen with GnRH agonists. Used in fertility protocols and studied for prostate conditions and hormonal management.

Primary Research Areas

  • HPG axis suppression
  • LH/FSH reduction
  • controlled ovarian stimulation support
  • testosterone management

Risk Profile

Medium Risk

Moderate risk profile in research contexts. Consult a healthcare professional before use.

Regulatory Status

Prescription OnlyFDA Approved

FDA-approved GnRH antagonist. Brand: Cetrotide (NDA 021036, Jun 1999). Prevents premature LH surges in controlled ovarian stimulation. Prescription only.

Effective: June 3, 1999View FDA source →

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find Cetrorelix

No active associated providers listed yet.